Ratings IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:23 2025-06-13 EDT			5-day change	1st Jan Change
11.25 ^GBX	-8.16%		0.00%	-4.26%

06-10	Ixico cheers FDA approval for contractor Fujirebio's Alzheimer's test	AN
06-10	IXICO plc Announces FDA Clearance of New Alzheimer's Disease Blood Based Diagnostic Biomarker	CI

Highlights: IXICO plc

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Historically, the company has been releasing figures that are above expectations.

Weaknesses: IXICO plc

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings Chart: IXICO plc

Source: Surperformance

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Capi.($)
IXICO PLC	-	-	14.17M
LONZA GROUP AG			49.5B
IQVIA HOLDINGS INC.			27.14B
CELLTRION, INC.			26.06B
EUROFINS SCIENTIFIC SE			12.53B
ICON PUBLIC LIMITED COMPANY			11.57B
QIAGEN N.V.			10.2B
Average			19.57B
Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes